BenevolentAI
using our platform for societal bene a covid treatment now approved for use by the non commercial collaboration rapid as a treatment in just hours published research in the lancet in novel our technology and work a previously unknown antiviral mechanism effective barrier trial showed reduces mortality by in patients and by in ventilated or patients focused on dengue fever a major burden aims to deliver biological targets and drug candidates experimental validation in progress assays approved the to treat covid in may after granting in led to equity investment from benefit lilt | BenevolentAI
Company
Deck Type
Deck date
March 2023
Slide
37 of 38
Similar slides by BenevolentAI
Investor Conference
January 2023
Related slides by other companies
Results
January 2023
Investor Presentation
February 2023
Investor Day
January 2022
Investor Presentation
November 2023
Other recent decks by BenevolentAI
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Investor Conference
January 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io